MARKET

ERNA

ERNA

Eterna Therapeutics Inc
NASDAQ
2.124
+0.124
+6.19%
Opening 09:36 05/20 EDT
OPEN
2.000
PREV CLOSE
2.000
HIGH
2.124
LOW
2.000
VOLUME
183
TURNOVER
0
52 WEEK HIGH
2.990
52 WEEK LOW
0.8401
MARKET CAP
11.49M
P/E (TTM)
-0.4995
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ERNA last week (0513-0517)?
Weekly Report · 8h ago
ERNA Stock Earnings: Eterna Therapeutics Reported Results for Q1 2024
Investorplace · 5d ago
Weekly Report: what happened at ERNA last week (0506-0510)?
Weekly Report · 05/13 10:26
Eterna Therapeutics Presents Development Of Beta 2 Microglobulin-Knockout iMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features That May Further Augment The Therapeutic Potential Of MSCs In Inflammatory Diseases At The ASGCT Annual Meeting
The presentation reports the development of a beta 2 microglobulin-knockout iMSC line with enhanced immunosuppressive activity and stealthing features. Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene + Cell Therapy. The presentation is on Saturday, May 11th, 2024.
Benzinga · 05/10 12:07
ETERNA THERAPEUTICS ANNOUNCES APPOINTMENT OF MAHENDRA RAO, PHD, TO ITS SCIENTIFIC ADVISORY BOARD
Reuters · 05/08 13:31
Press Release: Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board. Dr. Rao is internationally recognized for his research involving pluripotent stem cells. Eterna is a preclinical-stage biopharmaceutical company committed to realizing the potential of mRNA cell engineering.
Dow Jones · 05/08 13:31
Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout iMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features That May Further Augment The Therapeutic Potential Of MSCs In Inflammatory Diseases
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features. Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy. The presentation is on May 11th, 2024.
Benzinga · 05/07 12:04
Weekly Report: what happened at ERNA last week (0429-0503)?
Weekly Report · 05/06 10:31
More
About ERNA
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.

Webull offers Eterna Therapeutics Inc stock information, including NASDAQ: ERNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERNA stock methods without spending real money on the virtual paper trading platform.